Therefore, preclinical studies on the use of anti-MSTN antibodies in model animals subjected to limb unloading will be needed to confirm and validate the efficacy of this treatment in counteracting the loss of muscle mass typical of sarcopenia. Here, MSTN is linked to sarcopenia.